Login to Your Account



ICAAC Roundup


Tuesday, September 11, 2012
• Evolva Holding SA, of Reinach, Switzerland, presented preclinical data showing that EV-035 demonstrated a broad spectrum of activity in in vitro and in vivo studies against bacteria, including those resistant to older generations of antibiotics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription